Trouillet J L, Vuagnat A, Combes A, Kassis N, Chastre J, Gibert C
Hôpital Pitie-Salpêtrière, 75651 Paris Cedex 13, France.
Clin Infect Dis. 2002 Apr 15;34(8):1047-54. doi: 10.1086/339488. Epub 2002 Mar 15.
We sought to determine the epidemiological characteristics of patients in an intensive care unit (ICU) who developed ventilator-associated pneumonia (VAP) caused by piperacillin-resistant Pseudomonas aeruginosa (PRPA; n=34) or piperacillin-susceptible P. aeruginosa (PSPA; n=101). According to univariate analysis, the factors associated with the development of PRPA VAP were presence of an underlying fatal medical condition, immunocompromised status, longer previous hospital stay, less-severe illness at the time of ICU admission, duration of mechanical ventilation before onset of VAP, number of classes of antibiotic received, and previous exposure to imipenem or fluoroquinolone. Multivariate logistic regression analysis identified the following significant independent factors: presence of an underlying fatal medical condition (odds ratio [OR], 5.6), previous fluoroquinolone use (OR, 4.6), and initial disease severity (OR, 0.8). We concluded that the clinical characteristics of patients who develop PRPA VAP differ from those of patients who develop PSPA VAP. Restricted fluoroquinolone use is the sole independent risk factor for PRPA VAP that is open to medical intervention.
我们试图确定重症监护病房(ICU)中发生由耐哌拉西林铜绿假单胞菌(PRPA;n = 34)或哌拉西林敏感铜绿假单胞菌(PSPA;n = 101)引起的呼吸机相关性肺炎(VAP)患者的流行病学特征。根据单因素分析,与PRPA VAP发生相关的因素包括存在潜在致命性疾病、免疫功能低下状态、既往住院时间较长、ICU入院时病情较轻、VAP发作前机械通气时间、接受抗生素种类数量以及既往使用亚胺培南或氟喹诺酮类药物。多因素逻辑回归分析确定了以下显著独立因素:存在潜在致命性疾病(比值比[OR],5.6)、既往使用氟喹诺酮类药物(OR,4.6)以及初始疾病严重程度(OR,0.8)。我们得出结论,发生PRPA VAP的患者的临床特征与发生PSPA VAP的患者不同。限制氟喹诺酮类药物的使用是PRPA VAP唯一可通过医学干预的独立危险因素。